ClaimsPeople

Ray Kurzweil

Ray Kurzweil is an author of books on artificial intelligence and the technological singularity, including The Singularity Is Near, The Singularity Is Nearer, The Age of Spiritual Machines and How to Create a Mind; he received the 1999 National Medal of Technology and Innovation, became Director of Engineering at Google and co-founded Singularity University.

894 claims collected, 397 researched, 78 resolved. Report of 5 November 2026, method 0.1.0+28da144b.

Scores by kind of claim

Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.

  • Factual claims

    Statements about the present or the past, checked against the record: did they hold up?

    68 61 75

    High confidence, 69 factual claims resolved. From 13 documents, 2000 to 2026; 15 documents sampled from 30 candidates found.

    Not scored: 61 unresolvable, 14 checkable only against their own records.

  • Predictions

    Statements about events outside the person's control, checked once they fell due: did they come true?

    42 25 60

    Low confidence, 9 predictions resolved. From 4 documents, 2001 to 2020; 15 documents sampled from 30 candidates found.

    Not scored: 140 unresolvable, 2 checkable only against their own records. 98 more fall due later.

    Does not yet allow for how likely each prediction was when made.

  • Promises

    Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?

    Insufficient record: 0 promises resolved, 5 needed for a score.

    Not scored: 1 not yet due.

All types combined: 65 (likely 58 to 71, high confidence), from 78 claims: 69 factual claims, 9 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.

Ray Kurzweil's claims

9 claims

9 claims, sorted by newest said. Choose a claim to read it in full.
VerdictKindSaidClaimTopic
Mixed Factual Mar 2025 AI hallucinations persist but are becoming much less frequent. Factual · Mar 2025 AI capabilities
Mixed Factual Mar 2025 Kurzweil said that at about 10 billion connections neural networks started to do things. Factual · Mar 2025 AI compute, hardware and data
Mixed Factual Mar 2025 More and more people from more backgrounds, including third world countries in Africa and South America, now participate in technological advances than previously. Factual · Mar 2025 Economics and markets
Mixed Factual 9 Jul 2024 Among the forecasts he was describing, which averaged a hundred years, nobody said it would happen within 30 years, but now everybody is saying that. Factual · 9 Jul 2024 AI timelines and forecasting
Mixed Factual 9 Jul 2024 Cloud computing is expanding exponentially, doubling in speed every year for the same money. Factual · 9 Jul 2024 AI compute, hardware and data
Mixed Factual May 2020 The current method for testing the few treatments that are tried organizes a few hundred human subjects and tests them over about a year and a half, at a cost of hundreds of millions of dollars. Factual · May 2020 Science and research methods
Mixed Factual Mar 2017 In recent years Minsky lamented the 'success' of his book and had become respectful of recent gains in neural net technology. Factual · Mar 2017 AI capabilities
Mixed Factual Mar 2017 For every job that was eliminated, several new ones were invented, with the work force growing from 24 million people (31 percent of the population) in 1900 to 142 million (44 percent of the population) in 2015. Factual · Mar 2017 AI, the economy and work
Mixed Factual 23 Oct 2000 The 'immune system' that evolved in response to computer viruses has been largely effective. Factual · 23 Oct 2000 Technology
Back to the list

Ray Kurzweil

Open its page

Factual Science and research methods

“The current method for testing these few treatments is to organize a few hundred human subjects and then test them over about a year and a half, at a cost of hundreds of millions of dollars.”

Ray Kurzweil, columnist May 2020 AI-powered bio-tech can help deploy a vaccine in record time (Kurzweil Library / Wired)

The current method for testing the few treatments that are tried organizes a few hundred human subjects and tests them over about a year and a half, at a cost of hundreds of millions of dollars.

Mixed Partly true and partly false in roughly equal measure.

The second judge would not resolve this claim; the verdict shown is the first judge's.

Said for an organisation they lead or work for; it counts on both records.

What would count as true or false

Compare with typical clinical trial practice as of 2020. True: typical trials of candidate treatments involve a few hundred subjects, last about 1.5 years, and cost hundreds of millions of dollars. Mostly true: the description fits a common phase (e.g., Phase 2) with one detail somewhat off, such as cost being lower per trial but hundreds of millions across development. Mixed: two of the three elements (subjects, duration, cost) broadly hold and one is clearly off. Mostly false: only one element holds, or the description conflates trial phases in a distorting way. False: typical trials differ substantially on all three elements.

Evidence

  1. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 PMC (Moore et al., JAMA Internal Medicine) · 24 September 2018
    “the median estimated direct cost of pivotal efficacy trials was $19 million, with half of the trial cost estimates ranging from $12 million to $33 million. At the extremes of the distribution were 100-fold cost differences, and patient enrollment varied from fewer than 15 patients to more than 8000 patients.”
  2. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study PMC (BMJ Open) · 11 June 2020
    “The 225 individual clinical trials had a median estimate of US$19 million (IQR US$12 million–US$33 million) per trial and US$41 413 (IQR, US$29 894–US$75 047) per patient.”
  3. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study PMC (BMJ Open) · 11 June 2020
    “Although the trials enrolled a median of 495 patients there was wide variation, ranging from 4 patients to 8446 patients.”
  4. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study PMC (BMJ Open) · 11 June 2020
    “The estimated costs are modest for measuring the benefits of new therapeutic agents but rise exponentially as more patients and clinic visits are required to establish a drug effect.”

Reasoning

For pivotal trials supporting FDA approvals in 2015–2017, the median enrollment was 495 patients (E3), which fits "a few hundred" subjects. The median estimated cost per trial was about $19 million, with an interquartile range of $12–33 million (E1, E2). That is well below "hundreds of millions," so the cost element is clearly off. No evidence addresses the roughly 1.5-year duration, so only one element is confirmed and one is clearly wrong, which places the claim between mixed and mostly false.

Cite this claim

Ray Kurzweil, “The current method for testing the few treatments that are tried organizes a few hundred human subjects and tests them over about a year and a half, at a cost of hundreds of millions of dollars.” (said May 2020). Verdict: mixed. Reliability API, claim c_5029a99d673d, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_5029a99d673d

Claims without a verdict

Is a verdict here wrong, or do you speak for Ray Kurzweil? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.